XML 9 R2.htm IDEA: XBRL DOCUMENT v3.25.2
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2025
Dec. 31, 2024
Current assets:    
Cash and cash equivalents $ 36,491 $ 11,813
Short-term bank deposits 17,874 14,858
Notes receivable 499 4,373
Accounts receivables, net 24,629 19,589
Inventories, net 8,861 6,337
Prepaid assets and other current assets 2,701 2,625
Total current assets 91,285 64,786
Property and equipment, net 23,401 23,880
Intangible assets, net 4,962 273
Deferred tax assets 6,134 5,619
Long-term certificates of deposit 21,528 24,568
Other assets, noncurrent 5,336 6,280
Total assets 152,646 125,406
Current liabilities:    
Accounts payable 71 108
Contract liabilities 0 61
Due to related parties 219 227
Accrued expenses and other current liabilities 14,924 10,615
Income tax payable 1,084 2,831
Operating lease liabilities, current 622 713
CVR derivative liability 0 4,961
Total current liabilities 16,920 19,516
Operating lease liabilities, noncurrent 771 885
Deferred government grants 884 928
Warrant liability, noncurrent 3,201 5,668
Other noncurrent liabilities 1,427 7
Total liabilities 23,203 27,004
Commitments and Contingencies (Note 12)
Stockholders' equity:    
Common stock, $0.001 par value, 400,000,000 shares authorized; 90,822,828 shares and 86,307,544 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively 91 86
Additional paid-in capital 161,437 136,185
Statutory reserve 3,098 3,098
Accumulated deficit (70,313) (73,453)
Accumulated other comprehensive loss (2,287) (2,597)
Total Gyre stockholders' equity 92,026 63,319
Noncontrolling interest 37,417 35,083
Total equity 129,443 98,402
Total liabilities and stockholders' equity 152,646 125,406
GC Biopharma Corp    
Current assets:    
Receivable from GCBP 0 4,961
GNI    
Current assets:    
Other receivables from GNI $ 230 $ 230